NCT01508572View on ClinicalTrials.gov

VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

bevacizumab-IRDye800CW

In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

UMC Utrecht

OTHER

lead

University Medical Center Groningen

OTHER

NCT01508572 - VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer | Biotech Hunter | Biotech Hunter